REVERSAL Trial

	High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
REVERSAL Trial On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of REVERSAL Trial All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on REVERSAL Trial
CDC on REVERSAL Trial
REVERSAL Trial in the news
Blogs on REVERSAL Trial
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for REVERSAL Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective[edit | edit source]

To compare the effects of pravastatin and atorvastatin on coronary artery plaque burden and progression by intensive lipid lowering.

Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL] was a multicentered, randomized, double- blinded trial wherein 654 patients received the study drug. IVUS examinations were performed at baseline and after 18 months of treatment in 502 patients. Patients randomly received either 40 mg pravastatin or 80 mg of atorvastatin.

Results[edit | edit source]

The mean LDL-C levels reduced from 150 to 110 mg/dL in the pravastatin group and to 79 mg/dL in the atorvastatin. Percentage change in atheroma volume showed a significantly lower progression rate in the atorvastatin (intensive) group compared to the pravastatin group.

Conclusion[edit | edit source]

In patients with coronary artery disease, atorvastatin reduced progression of coronary atherosclerosis compared with pravastatin.^[1]

References[edit | edit source]

↑ "Effect of intensive compared with moderate lipid-loweri... [JAMA. 2004] - PubMed - NCBI".

[urlEffect_of_intensive_compared_with_moderate_lipid-loweri..._[JAMA._2004]_-_PubMed_-_NCBI-1] "Effect of intensive compared with moderate lipid-loweri... [JAMA. 2004] - PubMed - NCBI".

[1]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL

REVERSAL Trial

Objective[edit | edit source]

Methods[edit | edit source]

Results[edit | edit source]

Conclusion[edit | edit source]

References[edit | edit source]